VYCO
Vycor Medical, Inc.0.1600
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
5.34MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
8-K
Revenue up 31%, profit turns positive
Vycor Medical posted Q3 revenue of $514K, up 31% year-over-year, with VBAS surging 32% on US strength while nine-month growth hit 29% internationally. GAAP operating profit flipped to $32K from a loss; non-GAAP profit reached $60K (reconciled). Three new VBAS papers bolster clinical validation. Momentum builds.
10-Q
Q3 FY2025 results
Vycor Medical swung to Q3 operating income of $32K, up from a $35K loss y/y, while revenue jumped 31% to $514K on Vycor segment strength (32% y/y growth to $492K). Nine-month revenue rose 28% to $1.45M with operating income of $70K versus a $28K loss last year, though gross margins dipped to 88% from validation costs; YTD net loss narrowed to $10K from $100K, driven by preferred dividends. Cash fell to $64K amid $53K operating outflow, with $4.0M stockholders' deficiency from related-party notes ($493K) and EuroAmerican term note ($300K due March 2026 at 16%). Free cash flow not disclosed in the 10-Q. Vycor dominates US sales. Liquidity strains persist.
8-K
Q2 revenue up 22%
Vycor Medical posted Q2 revenue of $496k, up 22% YoY, with Vycor division surging 24% to $482k on international growth and new France/Spain deals. Operating profit hit $51k GAAP, $84k non-GAAP—both way up—despite gross margins dipping to 83% from production costs. Five VBAS papers published this half. NovaVision ticks along in development.
10-Q
Q2 FY2025 results
Vycor Medical posted Q2 revenue of $496k, up 22% y/y from $406k, with gross profit climbing 12% to $415k at 84% margin; Vycor segment drove $482k (97% of sales), up 24% y/y on international growth, while operating income surged to $51k from $16k. Six-month revenue hit $933k, +25% y/y, but YTD net loss of $15k (versus $41k prior) reflects $162k preferred dividends; EPS -$0.01 aligns with 33.4M basic shares, as dilution from 5.3M convertibles was anti-dilutive for YTD. Cash dipped to $100k with $20k operating cash flow, no capex detailed for FCF; debt includes $300k EuroAmerican note due September 2025 at 16% and $138k SBA EIDL at 3.75%. Vycor dominates US sales. Going concern doubts loom over liquidity.
8-K
Q1 revenue jumps 30%
Vycor Medical posted Q1 revenue of $436,378, up 30% from 2024, driven by 31% VBAS growth to $418,520—US hospitals one-third, international two-thirds. New deals in France and Spain fueled expansion; three VBAS papers spotlighted clinical wins. Non-GAAP operating profit hit $21,619. Gross margins dipped to 82%. NovaVision lags.
BSX
Boston Scientific Corporation
92.95+0.76
CLPT
ClearPoint Neuro Inc.
13.82+1.44
ENOV
Enovis Corporation
26.07-0.47
LIVN
LivaNova PLC
63.08+0.02
MASI
Masimo Corporation
134.52-2.88
NMTC
NeuroOne Medical Technologies C
0.71+0.05
NPCE
Neuropace, Inc.
15.88-0.04
NVCR
NovoCure Limited
12.93-0.04
SYK
Stryker Corporation
351.69-3.62
VTAK
Catheter Precision, Inc.
2.19-0.04